{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:16:42Z","timestamp":1793236602342,"version":"4.5.0"},"reference-count":37,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck","award":["10.13039\/100009945"],"award-info":[{"award-number":["10.13039\/100009945"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>For patients with locally advanced\/metastatic urothelial carcinoma (la\/mUC), first-line (1L) treatment with platinum-based chemotherapy (PBC) followed by avelumab 1L maintenance (1LM) is a recommended therapy per treatment guidelines in patients without disease progression. However, contemporary real-world (rw) data among patients receiving this treatment are necessary to understand clinical outcomes and optimal treatment sequencing. This retrospective cohort study analyzed rw treatment patterns and clinical outcomes, including overall survival (rwOS) and progression-free survival (rwPFS), in patients with la\/mUC receiving avelumab 1LM. From the Flatiron Health database, 214 patients who received avelumab 1LM following 1L PBC were included. From the start of avelumab 1LM, median rwOS was 23.8 months (95% CI: 18.2\u2014not estimable [NE]) and median rwPFS was 5.1 months (95% CI: 4.1\u20137.0). A total of 96 patients received second-line (2L) therapy, with 53 receiving enfortumab vedotin (EV). From the start of 2L EV, median rwOS was 11.2 months (95% CI: 6.8\u2014NE) and median rwPFS was 4.9 months (95% CI: 3.9\u20138.8). Treatment patterns and clinical outcomes in this study align with guidelines and outcomes observed in the JAVELIN Bladder 100 and EV-301 clinical trials and other rw studies, supporting the use of 1L PBC followed by avelumab 1LM and 2L EV for eligible patients.<\/jats:p>","DOI":"10.3390\/curroncol31090420","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T09:16:10Z","timestamp":1727428570000},"page":"5662-5676","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States"],"prefix":"10.3390","volume":"31","author":[{"given":"Helen H.","family":"Moon","sequence":"first","affiliation":[{"name":"Kaiser Permanente Southern California, Riverside, CA 92505, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"Kearney","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, 64293 Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hamidreza","family":"Mahmoudpour","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, 64293 Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiemeka","family":"Ike","sequence":"additional","affiliation":[{"name":"EMD Serono, Inc., Rockland, MA 02370, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-7379","authenticated-orcid":false,"given":"Valerie","family":"Morris","sequence":"additional","affiliation":[{"name":"EMD Serono, Inc., Rockland, MA 02370, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6740-4451","authenticated-orcid":false,"given":"Andrew","family":"Rava","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Kim","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Sun","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marley","family":"Boyd","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Gomez Rey","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"key":"ref_1","unstructured":"U.S. Cancer Statistics Working Group (2024, April 17). U.S. Cancer Statistics Data Visualizations Tool, Based on 2022 Submission Data (1999\u20132020), Available online: https:\/\/www.cdc.gov\/cancer\/dataviz."},{"key":"ref_2","unstructured":"American Cancer Society (2024, March 03). Key Statistics for Bladder Cancer. Available online: https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/key-statistics.html."},{"key":"ref_3","unstructured":"National Cancer Institute (2024, April 17). Cancer Stat Facts: Bladder Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"ref_4","unstructured":"(2024, May 16). National Comprehensive Cancer Network. Bladder Cancer (Version 4.2024). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: Results from the JAVELIN Bladder 100 trial after >\/=2 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1200\/JCO.2022.40.16_suppl.4577","article-title":"Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC)","volume":"40","author":"Gupta","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2018.36.15_suppl.4504","article-title":"Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)","volume":"36","author":"Rosenberg","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2018.36.15_suppl.4503","article-title":"First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_15","unstructured":"Birnbaum, B., Nussbaum, N., Seidl-Rathkopf, K., Agrawal, M., Est\u00e9vez, M., Estola, E., Haimson, J., He, L., Larson, P., and Richardson, P. (2020). [Pre-print] Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv."},{"key":"ref_16","unstructured":"Flatiron Health (2024, April 17). Quick Facts. Available online: https:\/\/flatiron.com\/media."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ma, X., Long, L., Moon, S., Adamson, B.J.S., and Baxi, S.S. (2020). Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRXiv.","DOI":"10.1101\/2020.03.16.20037143"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Public Policy Committee, and International Society of Pharmacoepidemiology (2016). Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol. Drug Saf., 25, 2\u201310.","DOI":"10.1002\/pds.3891"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/pds.4297","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making","volume":"26","author":"Berger","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_20","first-page":"1107","article-title":"The GRACE checklist: A validated assessment tool for high quality observational studies of comparative effectiveness","volume":"22","author":"Dreyer","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1200\/JCO.2023.41.16_suppl.4567","article-title":"Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC)","volume":"41","author":"Moon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S1215","DOI":"10.1016\/j.annonc.2023.09.1036","article-title":"2387P Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la\/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US","volume":"34","author":"Carson","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"Sonpavde","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2024.42.4_suppl.697","article-title":"Avelumab first-line maintenance therapy for locally advanced\/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study","volume":"42","author":"Grivas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2024.42.4_suppl.558","article-title":"Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"42","author":"Bracarda","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.2024.42.4_suppl.561","article-title":"Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment","volume":"42","author":"Barthelemy","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e249417","DOI":"10.1001\/jamanetworkopen.2024.9417","article-title":"Treatment patterns and attrition with lines of therapy for advanced urothelial carcinoma in the US","volume":"7","author":"Thomas","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2024.42.4_suppl.537","article-title":"Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study","volume":"42","author":"Nizam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1245\/s10434-020-08867-y","article-title":"Improving the quality of cancer care in community hospitals","volume":"28","author":"Tucker","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","unstructured":"Schlack, K., Sultanbaev, A., Lorente, D., Zihler, D., Kostkova, L., Cremer, L., and Gschwend, J. (2023, January 20\u201323). Baseline characteristics from AVENUE, a real-world observational study of avelumab first-line maintenance in patients with locally advanced\/metastatic urothelial carcinoma. Proceedings of the DGU 2023, Leipzig, Germany."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"TPS577","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS577","article-title":"SPADE: Design of a real-world observational study of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (UC) in the Asia-Pacific (APAC) region","volume":"41","author":"Su","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e16552","DOI":"10.1200\/JCO.2024.42.16_suppl.e16552","article-title":"Costs associated with novel first-line (1L) treatments in patients (pts) with locally advanced or metastatic urothelial carcinoma (la\/mUC) from a United States (US) Medicare and commercial payer perspective","volume":"42","author":"Ike","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s12094-023-03358-4","article-title":"Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial","volume":"26","author":"Climent","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_37","unstructured":"Witjes, J.A., Bruins, H.M., Carri\u00f3n, A., Cathomas, R., Comp\u00e9rat, E.M., Efstathiou, J.A., Fietkau, R., Gakis, G., van der Heijden, A.G., and Lorch, A. (2024). EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer, EAU Guidelines Office."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/420\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:01:28Z","timestamp":1760112088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["curroncol31090420"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31090420","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]}}}